PHARMACOLOGY OF ETROLIZUMAB IN A PHASE 2 STUDY IN MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS

(1) Genentech, Inc., South San Francisco, United States

(2) Hospital Clinic De Barcelona, Barcelona, Spain

(3) University Of Leuven, Leuven, Belgium

(4) University Of Newcastle , Newcastle Upon Tyne, United Kingdom

(5) University Of Western Ontario, London, Canada

(6) Humboldt-University Of Berlin, Berlin, Germany

(7) Christian Albrechts University, Kiel, Germany

(8) Tel Aviv University, Tel Aviv, Israel

(9) University Of California San Diego, La Jolla, United States



This item was part of UEG Week 2014

This item can be cited as: United European Gastroenterology Journal; 2014: 2 (Supplement 1)